Information  X 
Enter a valid email address

Byotrol PLC (BYOT)

  Print          Annual reports

Friday 13 November, 2020

Byotrol PLC

AGM Statement

RNS Number : 1961F
Byotrol PLC
13 November 2020





Byotrol plc





Byotrol plc (AIM: BYOT), the specialist infection prevention and control company, makes the following statement ahead of the Company's AGM later today.


The Directors are pleased to report that trading remains at healthy levels, across all business units and product sales. Demand for IP licensing remains robust, with the team exploring multiple new opportunities both in the UK and internationally.


The Group's net cash position remains strong, enabling us to maintain stock levels to fulfil customer demand or where appropriate re-invest for the growth of the business.


We expect results for the year to 31 March 2021 to meet current market expectations, notwithstanding the recent news on the development of potential vaccines against Covid-19. This is supported by industry trends clearly in evidence before (and now magnified by) Covid-19, all of which continue to favour Byotrol's long-term positioning, notably:


  businesses and consumers taking increasingly proactive responsibility for protecting individuals against infection risk from viruses and bacteria, so increasing global demand; and


  competitors with weaker performance chemistries continuing to withdraw from our market in the UK and Europe as new regulations take hold, so reducing the supply of competing products and so multiplying opportunities for Byotrol's future growth.


The Directors remain highly confident in Byotrol's longer term outlook.




Byotrol plc

David Traynor, Chief Executive Officer

Nic Hellyer, Chief Financial Officer    01925 742 000



Geoff Nash/Kate Bannatyne - Corporate Finance         020 7220 0500

Richard Chambers - ECM


Flagstaff Strategic and Investor Communications

Tim Thompson/Andrea Seymour/Fergus Mellon               020 7129 1474

[email protected]



Notes to Editors:


Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.


Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.


Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.


For more information, please go to


 This announcement is released by Byotrol plc and, prior to publication, the information contained herein was deemed to constitute inside information under the Market Abuse Regulations (EU) No. 596/2014. Such information is disclosed in accordance with the Company's obligations under Article 17 of MAR.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t